Non Small Cell Lung Cancer
Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available.
A drug holds lung cancer at bay longer after surgery than standard chemotherapy, according to unpublished results of a new trial in China.
The first findings from the Cancer Research UK-funded TRACERx* lung cancer study show how tracking tumour evolution can help predict relapse.
A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects.
Syncona LLP and Cancer Research Technology (CRT) announce the formation of Achilles Therapeutics Ltd today.
Patients with non-small cell lung cancer which has spread to the brain could be spared whole brain radiotherapy.
Scientists have shown that a drug combination slows cancer cell growth in a type of non-small cell lung cancer when tested in the lab.
A combination of two immunotherapy drugs outperformed a single drug treatment in patients with a type of advanced lung cancer.
Analysing tumour DNA in blood samples could help doctors offer ‘targeted’ treatments best suited to a patient’s lung cancer.
Thousands of cancer patients are missing out on personalised treatments each year because they are not being tested to see if they might benefit from them